JAK2 and polycythemia: In a murine model of JAK2 p.V617F-driven PV, genetic deletion or pharmacologic inhibition of OSM reduced polycythemia, spleen size, BM fibrosis and the levels of proinflammatory cytokines, establishing OSM as a critical mediator of oncogene-induced inflammation and immune suppression.